WAYNE, Pa.--(BUSINESS WIRE)--Feb. 24, 2016--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, announced it has received
FDA 510(k) clearance to market a newly designed Arrow® VPS®
Stylet. The new design allows Teleflex to provide hospitals with a
complete offering of single, double and triple lumen pre-loaded,
pressure injectable Arrow® PICC with Chlorag+ard®
Technology for use with its current Arrow® VPS®
Device platform. Together these technologies provide an easy solution
for clinicians who are dedicated to reducing central venous catheter
malposition while helping prevent microbial colonization and thrombus
accumulation on catheter surfaces.
Eliminating chest X-ray, reducing patient exposure to radiation and
providing protection against microbial colonization and thrombus
accumulation on catheter surfaces is easier than ever now that the
single, double and triple lumen Arrow® PICC with Chlorag+ard®
Technology is available pre-loaded with the Arrow® VPS®
Stylet.
The Arrow® VPS® Device is designed to replace the
need for confirmatory chest X-ray in the presence of a steady Blue
Bullseye by using state-of-the-art, real-time intravascular Doppler, ECG
and advanced algorithmic logic to notify the clinician that the catheter
tip has reached the optimal location.
“Vascular access procedures are one of the most commonly performed in
the hospital but are inherently high risk. This has a major impact on
hospital reimbursement under the Affordable Healthcare Act," said Jay
White, President of the Vascular Division of Teleflex. "We are proud to
now provide a full offering of pre-loaded Arrow® PICC with
Chlorag+ard® Technology for use with our innovative Arrow®
VPS® Devices. The combination of these leading technologies
allows us to provide cutting-edge tools to help improve patient outcomes
and help solve problems faced by the vascular access clinician every
day."
Additional information may be found at www.arrowvascular.com/vps,
www.chloragard.com
and www.teleflex.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rüsch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Chlorag+ard, Deknatel, Hudson
RCI, LMA, Pilling, Rüsch, VPS, VPS G4 and Weck are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates, in the
U.S. and/or other countries.
© 2016 Teleflex Incorporated.
All rights reserved. MC-002067
View source version on businesswire.com: http://www.businesswire.com/news/home/20160224006217/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836